Diffuse large B-cell lymphoma
LH Sehn, G Salles - New England Journal of Medicine, 2021 - Mass Medical Soc
LH Sehn, G Salles
New England Journal of Medicine, 2021•Mass Medical SocDiffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially,
with another 20 to 25% cured with salvage therapy. Efforts are ongoing to tailor therapy to
particular genetic lesions.
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially,
with another 20 to 25% cured with salvage therapy. Efforts are ongoing to tailor therapy to
particular genetic lesions.
Diffuse Large B-Cell Lymphoma
DLBCL, an aggressive cancer, accounts for about 30% of all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially, with another 20 to 25% cured with salvage therapy. Efforts are ongoing to tailor therapy to particular genetic lesions.
The New England Journal Of Medicine